Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1987 Apr;55(4):990–994. doi: 10.1128/iai.55.4.990-994.1987

Protective immunity in toxoplasmosis: correlation between antibody response, brain cyst formation, T-cell activation, and survival in normal and B-cell-deficient mice bearing the H-2k haplotype.

V Brinkmann, J S Remington, S D Sharma
PMCID: PMC260450  PMID: 3493977

Abstract

Correlations of Toxoplasma gondii-specific immunoglobulin M (IgM) and IgG production, antigen-specific T-cell activation, and the number of brain cysts were compared in immunocompetent CBA/J (H-2k), C3H/He (H-2k), and B-cell-deficient CBA/N (H-2k) mice. Almost all of the C3H/He mice (94%) survived in comparison to CBA/J (71%) and CBA/N (53%) mice following infection with 20 cysts of Me 49, an avirulent strain of T. gondii. The mortality in susceptible mice was reduced by treatment of the animals with sulfadiazine during the acute stage of infection. Decreased mortality in CBA/J and C3H/He mice as well as in B-cell-deficient mice was paralleled by formation of fewer brain cysts. The Toxoplasma-specific T-cell proliferation was markedly enhanced in all three strains at day 15 postinfection but not at day 45 postinfection when compared to animals not treated with the drug. In contrast, Toxoplasma-specific IgM and IgG levels were lower in CBA/J and CBA/N mice treated with sulfadiazine than in untreated mice of these strains. Although CBA/N mice developed almost no humoral response either with or without drug treatment, they produced fewer brain cysts than normal CBA/J mice. The results indicate a major role of cell-mediated immunity in protection against an acute Toxoplasma infection.

Full text

PDF
990

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amsbaugh D. F., Hansen C. T., Prescott B., Stashak P. W., Barthold D. R., Baker P. J. Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J Exp Med. 1972 Oct 1;136(4):931–949. doi: 10.1084/jem.136.4.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arend W. P., Sturge J. C. Composition and biologic properties of soluble IgG-anti-IgG immune complexes: effects of variations in the specificity of rabbit antibodies to different structural components of human IgG. J Immunol. 1979 Jul;123(1):447–454. [PubMed] [Google Scholar]
  3. Brinkmann V., Sharma S. D., Remington J. S. Different regulation of the L3T4-T cell subset by B cells in different mouse strains bearing the H-2k haplotype. J Immunol. 1986 Nov 1;137(9):2991–2997. [PubMed] [Google Scholar]
  4. CASEY A. E., CASEY J. G., HATHAWAY C. O., DOWLING E. A. Enhanced tumor homografts following pretreatment of donor mice. Proc Soc Exp Biol Med. 1959 Apr;100(4):762–763. doi: 10.3181/00379727-100-24770. [DOI] [PubMed] [Google Scholar]
  5. Camargo M. E., Ferreira A. W., Mineo J. R., Takiguti C. K., Nakahara O. S. Immunoglobulin G and immunoglobulin M enzyme-linked immunosorbent assays and defined toxoplasmosis serological patterns. Infect Immun. 1978 Jul;21(1):55–58. doi: 10.1128/iai.21.1.55-58.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Desmonts G., Remington J. S. Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity. J Clin Microbiol. 1980 Jun;11(6):562–568. doi: 10.1128/jcm.11.6.562-568.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. FRENKEL J. K. Pathogenesis of toxoplasmosis with a consideration of cyst rupture in Besnoitia infection. Surv Ophthalmol. 1961 Dec;6:799–825. [PubMed] [Google Scholar]
  8. Frenkel J. K., Taylor D. W. Toxoplasmosis in immunoglobulin M-suppressed mice. Infect Immun. 1982 Oct;38(1):360–367. doi: 10.1128/iai.38.1.360-367.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gaines J. D., Araujo F. G., Krahenbuhl J. L., Remington J. S. Simplified in vitro method for measuring delayed hypersensitivity to latent intracellular infection in man (toxoplasmosis). J Immunol. 1972 Jul;109(1):179–182. [PubMed] [Google Scholar]
  10. Gill H. S., Prakash O. Chemotherapy of experimental Toxoplasma gondii (RH strain) infection. Indian J Med Res. 1970 Sep;58(9):1197–1202. [PubMed] [Google Scholar]
  11. Honda M., Chan C., Shevach E. M. Characterization and partial purification of a specific interleukin 2 inhibitor. J Immunol. 1985 Sep;135(3):1834–1839. [PubMed] [Google Scholar]
  12. Jerusalem C., Weiss M. L., Poels L. Immunologic enhancement in malaria infection (Plasmodium berghei). J Immunol. 1971 Jul;107(1):260–268. [PubMed] [Google Scholar]
  13. Johnson A. M., McDonald P. J., Neoh S. H. Monoclonal antibodies to Toxoplasma cell membrane surface antigens protect mice from toxoplasmosis. J Protozool. 1983 May;30(2):351–356. doi: 10.1111/j.1550-7408.1983.tb02929.x. [DOI] [PubMed] [Google Scholar]
  14. KALISS N., SNELL G. D. The effects of injections of lyophilized normal and neoplastic mouse tissues on the growth of tumor homiotransplants in mice. Cancer Res. 1951 Feb;11(2):122–126. [PubMed] [Google Scholar]
  15. Krahenbuhl J. L., Blazkovec A. A., Lysenko M. G. In Vivo and In Vitro Studies of Delayed-Type Hypersensitivity to Toxoplasma gondii in Guinea Pigs. Infect Immun. 1971 Feb;3(2):260–267. doi: 10.1128/iai.3.2.260-267.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Krahenbuhl J. L., Gaines J. D., Remington J. S. Lymphocyte transformation in human toxoplasmosis. J Infect Dis. 1972 Mar;125(3):283–288. doi: 10.1093/infdis/125.3.283. [DOI] [PubMed] [Google Scholar]
  17. Krahenbuhl J. L., Ruskin J., Remington J. S. The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol. 1972 Feb;108(2):425–431. [PubMed] [Google Scholar]
  18. Lindberg R. E., Frenkel J. K. Toxoplasmosis in nude mice. J Parasitol. 1977 Apr;63(2):219–221. [PubMed] [Google Scholar]
  19. Remington J. S., Cavanaugh E. N. Isolation of the encysted form of Toxoplasma gondii from human skeletal muscle and brain. N Engl J Med. 1965 Dec 9;273(24):1308–1310. doi: 10.1056/NEJM196512092732404. [DOI] [PubMed] [Google Scholar]
  20. Sabin A. B., Feldman H. A. Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science. 1948 Dec 10;108(2815):660–663. doi: 10.1126/science.108.2815.660. [DOI] [PubMed] [Google Scholar]
  21. Scher I., Frantz M. M., Steinberg A. D. The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain. J Immunol. 1973 May;110(5):1396–1401. [PubMed] [Google Scholar]
  22. Sharma S. D., Araujo F. G., Remington J. S. Toxoplasma antigen isolated by affinity chromatography with monoclonal antibody protects mice against lethal infection with Toxoplasma gondii. J Immunol. 1984 Dec;133(6):2818–2820. [PubMed] [Google Scholar]
  23. Sharma S. D., Mullenax J., Araujo F. G., Erlich H. A., Remington J. S. Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol. 1983 Aug;131(2):977–983. [PubMed] [Google Scholar]
  24. Tremonti L., Walton B. C. Blast transformation and migration-inhibition in toxoplasmosis and leishmaniasis. Am J Trop Med Hyg. 1970 Jan;19(1):49–56. doi: 10.4269/ajtmh.1970.19.49. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES